Hemophilia A via the F8 Gene
Use
This test is designed for males with a clinical or suspected diagnosis of Hemophilia A, as well as females with clinical findings, laboratory findings, or a family history suggestive of Hemophilia A. It helps confirm the diagnosis of Hemophilia A and may identify carriers in the family. This is particularly useful for individuals looking to understand their genetic predisposition or family members who might be at risk.
Special Instructions
The test leverages Next-Generation Sequencing (NGS) with CNV analysis using Exome or Genome platforms. Patients are advised to contact PreventionGenetics for any specific queries related to testing particulars, and institutional pricing is available upon signing in. It is important for healthcare providers to obtain informed consent from patients and their family members prior to testing.
Limitations
The test has not been cleared or approved by the US Food and Drug Administration. It is developed and validated following College of American Pathologists (CAP) and Clinical Laboratory Improvements Amendments (CLIA) regulations, but regulatory constraints may exist in some jurisdictions, requiring healthcare providers to verify compliance. Diagnostic limitations pertain to detecting the specific genetic mutations or CNVs underlying Hemophilia A.
Methodology
NGS (Targeted)
Biomarkers
Result Turnaround Time
14-21 days
Related Documents
For more information, please review the documents below
Specimen
Whole Blood
Volume
Not provided
Minimum Volume
Not provided
Collection Instructions
Exome Platform: Blood samples are collected for testing. Follow standard procedures for collection and handling.